GSK to develop ofatumumab in autoimmune indications

GlaxoSmithKline Plc and Genmab A/S have altered their co-development agreement for ofatumumab (Arzerra) with the result that GSK will develop the antibody for autoimmune indications. The companies will continue their collaboration in cancer.